Scancell welcomes Susan Clement Davies to its Board as Non-Executive Director

– UK, Nottingham –  Scancell Holdings plc (LON: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announced the appointment of Susan Clement Davies to its Board as a Non-Executive Director with immediate effect.

Dr Alan Lewis is standing down from the Board as Non-Executive Director with immediate effect.

I am very pleased to welcome Susan to the Board of Scancell. Susan’s considerable experience in investment banking will be invaluable for any potential future licensing and corporate transactions.” said Board Chairman, Dr John Chiplin.

He added: “On behalf of the Board, I would like to take this opportunity to thank Alan Lewis for the contributions he has made to the Company since he was first appointed to the Board in 2016 and wish him all the best for the future.”

About Susan Clement Davies

Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and most recently until 2018, Managing Director at Torreya Partners LLC, a global investment banking firm serving companies in the Life Sciences industry. Her work at this time included providing advice on M&A, corporate finance, licensing transactions and pharmaceutical asset sales, with clients ranging from large pharmaceutical companies through to private equity firms focused on healthcare. Susan is currently Non-Executive Director and Chairman of the Audit Committee of Evgen Pharma plc, an AIM-listed clinical-stage drug development company.

Susan Clement Davies commented: “I am delighted to be joining the Scancell Board at this very exciting time and look forward to working with the team to maximise the potential value of the Company’s platform technologies.”

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer-based on its ImmunoBody and Moditope technology platforms.

ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

Moditope represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

Modi-1 is being developed for the treatment of solid tumours including triple-negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab is a patent-protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell’s anti-glycan monoclonal antibodies but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19. The Company believes this combined T cell and antibody approach should give more potent and long-lasting responses, ultimately leading to better protection.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.